» Articles » PMID: 24147489

Fusion Imaging-guided Radiofrequency Ablation for Hepatocellular Carcinomas Not Visible on Conventional Ultrasound

Overview
Specialties Oncology
Radiology
Date 2013 Oct 24
PMID 24147489
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The objective of our study was to assess whether fusion imaging of conventional ultrasound and liver CT or MR images can improve the conspicuity of lesions and feasibility of percutaneous radiofrequency ablation (RFA) for the treatment of hepatocellular carcinomas (HCCs) not visible on ultrasound. Whether peritumoral anatomic landmarks can be used for the placement of an electrode in HCCs not visible on ultrasound even after image fusion was also evaluated.

Materials And Methods: Planning ultrasound for percutaneous RFA was performed using conventional ultrasound first and then using fusion imaging later during the same session. The visibility of HCCs and feasibility of RFA on conventional ultrasound and on fusion imaging were assessed. We evaluated how many HCCs initially not visible on conventional ultrasound could be visualized and ablated after applying the fusion imaging technique. One hundred twenty HCCs not visible on conventional ultrasound in 96 patients were included.

Results: When fusion imaging was applied, 38 of the 120 (31.7%) HCCs that were initially not visible could be seen and RFA was feasible. Among the remaining 82 HCCs still not visible after image fusion, 26 (31.7%) were ablated under the guidance of fusion imaging the technique based on peritumoral anatomic landmarks. Overall, 64 of 120 (53.3%) HCCs (59.4%, 57 of 96 patients) not visible on conventional ultrasound could be ablated under the guidance of the fusion imaging technique.

Conclusion: Fusion imaging can improve the conspicuity of HCCs and the feasibility of percutaneous RFA of HCCs not visible on conventional ultrasound. Peritumoral anatomic landmarks can be used for electrode placement in HCCs that are still not visible even after image fusion.

Citing Articles

Ablation manual for liver cancer.

Maruyama H, Minami Y, Sugimoto K, Funaoka A, Numata K J Med Ultrason (2001). 2024; 52(1):27-53.

PMID: 39395134 PMC: 11799107. DOI: 10.1007/s10396-024-01499-9.


Local Ablation for Hepatocellular Carcinoma: 2024 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association.

Han S, Sung P, Park S, Kim J, Hong H, Yoon J Gut Liver. 2024; 18(5):789-802.

PMID: 39223081 PMC: 11391139. DOI: 10.5009/gnl240350.


Local ablation for hepatocellular carcinoma: 2024 expert consensus-based practical recommendation of the Korean Liver Cancer Association.

Han S, Sung P, Park S, Kim J, Hong H, Yoon J J Liver Cancer. 2024; 24(2):131-144.

PMID: 39210668 PMC: 11449576. DOI: 10.17998/jlc.2024.08.04.


Local Ablation for Hepatocellular Carcinoma: 2024 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association.

Han S, Sung P, Park S, Kim J, Hong H, Yoon J Korean J Radiol. 2024; 25(9):773-787.

PMID: 39197823 PMC: 11361797. DOI: 10.3348/kjr.2024.0550.


Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma.

Bajestani N, Wu G, Hussein A, Makary M Biomedicines. 2024; 12(7).

PMID: 39062006 PMC: 11274263. DOI: 10.3390/biomedicines12071432.